Health Care·Health Care Equipment·$92.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.41 | N/A | +3.27% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.41 | N/A | +3.27% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, no specific revenue guidance was provided.
We are pleased with our EPS performance this quarter.
Our focus remains on innovation and growth in key markets.
Boston Scientific's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 1.33%, likely due to the lack of revenue details and guidance, which may have left investors uncertain about future performance. The cautious tone from management suggests they are focused on long-term growth despite current market challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KIMBERLY CLARK CORP
Oct 25, 2021